Severe Acute Respiratory Syndrome in Children

Lauren J. Stockman, MPH*†; Mehran S. Massoudi, PhD, MPH*; Rita Helfand, MD*; Dean Erdman, DrPH*; Alison M. Siwek, MPH*†; Larry J. Anderson, MD*; Umesh D. Parashar, MD, MPH*


Pediatr Infect Dis J. 2007;26(1):68-74. 

In This Article


Because of the severe consequences of SARS-CoV disease and the potential for SARS outbreaks to cause substantial social disruption and economic impact, vaccines are being developed against SARS-CoV. Vaccines based on whole SARS virus inactivated with formaldehyde, ultraviolet light and β-propiolactone are being evaluated in clinical trials in China, but safety concerns remain about exposure of production workers to live SARS-CoV in the manufacturing process and from the potential for disease from incompletely inactivated virus. The spike (S) protein of SARS-CoV is responsible for the virus binding to the cell, fusion and entry into cells and is a major inducer of neutralizing antibodies. Recombinant vaccines expressing the SARS-CoV S protein or a specific receptor binding domain of the S protein are being evaluated.[44] Other strategies to develop SARS vaccines also are being pursued.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.
Post as: